Profile data is unavailable for this security.
About the company
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
- Revenue in USD (TTM)0.00
- Net income in USD-74.88m
- Incorporated2015
- Employees55.00
- LocationFulcrum Therapeutics Inc26 Landsdowne StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 651-8851
- Fax+1 (302) 655-5049
- Websitehttps://www.fulcrumtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 475.90m | 227.00 | -- | 1.18 | -- | 3,965.86 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 481.54m | 123.00 | -- | 38.39 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 482.06m | 17.00 | -- | 2.72 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 216.11m | -220.47m | 482.91m | 533.00 | -- | 1.48 | -- | 2.23 | -3.74 | -3.74 | 3.67 | 5.54 | 0.3774 | 7.29 | 4.25 | 405,450.30 | -38.51 | -6.49 | -48.99 | -7.64 | 93.96 | 92.12 | -102.02 | -17.46 | 2.38 | -- | 0.0224 | -- | 8.72 | -2.73 | -1,066.53 | -- | -11.08 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 483.04m | 100.00 | -- | 2.22 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 486.15m | 129.00 | -- | 2.45 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Prothena Corporation PLC | 9.68m | -244.09m | 506.03m | 67.00 | -- | 1.80 | -- | 52.25 | -4.53 | -4.53 | 0.1799 | 5.21 | 0.0222 | -- | -- | 144,537.30 | -55.86 | -19.16 | -62.22 | -20.73 | -- | -- | -2,520.57 | -114.82 | -- | -- | 0.00 | -- | -92.84 | 62.56 | -99.57 | -- | -6.78 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 511.98m | 300.00 | -- | 1.41 | -- | 12,487.30 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 517.81m | 263.00 | -- | -- | -- | 6.88 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 520.15m | 55.00 | -- | 1.49 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 520.40m | 72.00 | -- | 3.24 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 527.34m | 95.00 | -- | 3.92 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 539.59m | 202.00 | -- | 1.94 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 541.78m | 65.00 | -- | 3.22 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 560.36m | 41.00 | -- | 2.48 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Fulcrum Therapeutics Inc's reporting currency: US Dollar USD
52.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 31 Dec 2025 | 6.56m | 9.95% |
| RA Capital Management LPas of 31 Dec 2025 | 6.05m | 9.18% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 4.29m | 6.51% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.64m | 5.52% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.21m | 4.87% |
| Braidwell LPas of 31 Dec 2025 | 3.06m | 4.64% |
| Point72 Asset Management LPas of 31 Dec 2025 | 2.40m | 3.64% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.91m | 2.90% |
| First Turn Management LLCas of 31 Dec 2025 | 1.89m | 2.87% |
| Adage Capital Management LPas of 31 Dec 2025 | 1.70m | 2.58% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
